[Anti-osteoporosis drugs : their characteristics and evidence for anti-fracture efficacy].
Remarkable progress in development of anti-fracture drugs has been achieved. Now we have anti-resorptive drugs, bisphosphonates and selective estrogen receptor modulators (SERMs) , bone anabolic one, teriparatide, and active vitamin D(3) analogues, alfacalcidol and eldecalcitol. Accumulating evidence shows their anti-fracture efficacy and safety profiles. We should learn fundamental evidence of those medicines as prescribing them to patients with osteoporosis.
Toranomon Hospital Endocrine Center, Japan.
Yasuhiro
Y
Takeuchi
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators